Literature DB >> 25211865

Prospects for a dengue vaccine: progress and pitfalls.

Sarah L George.   

Abstract

Dengue virus is now the world's most common arboviral infection and has spread to the continental United States. The Aedes mosquito which transmits dengue is prevalent throughout Missouri, so clinicians should be familiar with dengue. While there are no licensed vaccines, five are in human trials including two tested at the Saint Louis University Center for Vaccine Development. Our deepening understanding of the correlates of protective immunity to dengue improves near-term prospects for a vaccine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25211865      PMCID: PMC6179479     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  24 in total

1.  Locally acquired Dengue--Key West, Florida, 2009-2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-21       Impact factor: 17.586

2.  Short report: immune response and occurrence of dengue infection in thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine.

Authors:  Pornthep Chanthavanich; Christine Luxemburger; Chukiat Sirivichayakul; Keswadee Lapphra; Krisana Pengsaa; Sutee Yoksan; Arunee Sabchareon; Jean Lang
Journal:  Am J Trop Med Hyg       Date:  2006-07       Impact factor: 2.345

3.  Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection.

Authors:  Kamolwish Laoprasopwattana; Daniel H Libraty; Timothy P Endy; Ananda Nisalak; Supamit Chunsuttiwat; David W Vaughn; George Reed; Francis A Ennis; Alan L Rothman; Sharone Green
Journal:  J Infect Dis       Date:  2005-07-05       Impact factor: 5.226

Review 4.  From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Authors:  Bruno Guy; Beatrice Barrere; Claire Malinowski; Melanie Saville; Remy Teyssou; Jean Lang
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

5.  Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.

Authors:  William B Messer; Ruklanthi de Alwis; Boyd L Yount; Scott R Royal; Jeremy P Huynh; Scott A Smith; James E Crowe; Benjamin J Doranz; Kristen M Kahle; Jennifer M Pfaff; Laura J White; Carlos A Sariol; Aravinda M de Silva; Ralph S Baric
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-02       Impact factor: 11.205

6.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

7.  A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Daniel Elwood; Catherine J Larsson; Janet C Lindow; Cecilia Tibery; Beulah P Sabundayo; Donna Shaffer; Kawsar R Talaat; Noreen A Hynes; Kimberli Wanionek; Marya P Carmolli; Catherine J Luke; Brian R Murphy; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2013-01-17       Impact factor: 5.226

Review 8.  New opportunities for control of dengue virus.

Authors:  Catherine H Roberts; Juthathip Mongkolsapaya; Gavin Screaton
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

9.  Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion.

Authors:  S B Halstead
Journal:  Yale J Biol Med       Date:  1970-04

10.  A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.

Authors:  Stephen J Thomas; Kenneth H Eckels; Isabelle Carletti; Rafael De La Barrera; Francis Dessy; Stefan Fernandez; Robert Putnak; Jean-Francois Toussaint; Wellington Sun; Kristen Bauer; Robert V Gibbons; Bruce L Innis
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.